News for NeuroSense Therapeutics Ltd Stock (NRSN)

NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022

PRNewsWire • 05/23/22

NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS

PRNewsWire • 04/11/22

NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC

PRNewsWire • 04/06/22

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

Seeking Alpha • 03/31/22

12 Stocks Halted On A Circuit Breaker This Week

Benzinga • 03/25/22

NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises

PRNewsWire • 03/25/22

Neurosense multiplies investor value 3X. Buy the penny stock and wait

Invezz • 03/22/22

Why Is NeuroSense Therapeutics (NRSN) Stock Up 300% Today?

InvestorPlace • 03/21/22

Hottest Penny Stocks To Watch as March Comes to an End

PennyStocks • 03/21/22

NeuroSense Shares Surge Over 400% As FDA Clears Initiating Pharmacokinetic Study Of PrimeC

Benzinga • 03/21/22

Why NeuroSense Shares Are Soaring Today

Benzinga • 03/21/22

NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS

PRNewsWire • 03/21/22

NeuroSense Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m.

PRNewsWire • 03/15/22

NeuroSense Therapeutics Granted Key Patent for its ALS Drug PrimeC in Australia

PRNewsWire • 03/01/22

Top Penny Stocks to Buy in March 2022, 3 For Your List

PennyStocks • 02/28/22

NeuroSense Therapeutics to Present at American Society for Experimental Neurotherapeutics Annual Meeting on March 3rd

PRNewsWire • 02/24/22

NeuroSense Therapeutics to Present at Aegis Virtual Conference

PRNewsWire • 02/22/22

NeuroSense Therapeutics to Present at BIO CEO & Investor Conference

PRNewsWire • 01/31/22

NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital

PRNewsWire • 01/27/22

NeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study Results at Four International Conferences

PRNewsWire • 01/04/22

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

Seeking Alpha • 12/22/21

NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team

PRNewsWire • 12/21/21

NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market

PRNewsWire • 12/13/21